Become A Featured Company

Exclusive Q&A Interview With Constance Therapeutics Founder and CEO, Constance Finley

Abbie Rosner

November 15th, 2018

News, Top News

After her home-crafted cannabinoid concentrates helped Constance Finley overcome a life-threatening illness, she went on to become a pioneer in developing top quality, high-dose THC and CBD extractions.  Since 2008, Finley has parlayed her proprietary extraction know-how to help thousands of patients with end-stage cancer and other severe conditions. Uncompromising in her approach to product quality and legal compliance, Finley has successfully navigated her company, Constance Therapeutics, through California’s stormy regulatory waters, to national and international prominence. In this interview, she talks about her company’s origins, its globally-expanding business frontiers, and collaborative R&D activities.

Constance Finley

AR: What inspired you to start Constance Therapeutics?

CF:  In the early 2000’s I was dying from a severe autoimmune condition. Friends recommended that I try cannabis, and in spite of my skepticism, I found that smoking it provided more relief than the 60-plus prescription drugs I had been taking. Because of my delicate condition, smoking wasn’t a sustainable option for me, so I learned how to produce concentrates, focusing on keeping the process pure and toxin-free. And while it was standard practice at the time to use leaf trimmings to make cannabis extractions, I used the premium, cannabinoid- and terpene-rich buds. Working systematically, I developed my own clean extraction system that yielded cannabinoid levels the testing labs had never seen before. During those years, I standardized and professionalized extraction, and became one of the mothers of modern cannabis extraction.

To comply with California’s Proposition 215, in 2008 I started a collective to legally produce cannabis extracts that would help myself and others. In 2014, I established Constance Therapeutics, to develop the business beyond treating local patients, and to protect my proprietary extraction and compounding methodologies.

People often think of cannabis as a commodity, but there is a growing understanding that everything we do, in terms of plant genetics and processing, directly affects the results. Cannabis is so broadly helpful, there are people who are curing themselves from pancreatic cancer with products they get from a dispensary.  The problem is, you never really know what you get off the shelf – and studies have shown that a high percentage of these products are tainted with toxins.  So if you truly want a clean product that has been targeted and provided relief for thousands of critically ill patients, that is backed up with research and verified outcomes, then you come to us.

AR: How has Constance Therapeutics been able to successfully negotiate California’s new, restrictive regulatory environment?

In order to survive 10 years in this industry, we’ve had to be both incredibly nimble and also stubbornly perseverant.  We’ve been absolute sticklers in not breaking any laws – even when there was so much confusion, it was hard to know what not to do.  

When the regulations came into California, they were something we wanted and desperately needed. But once that card was played, things kind of went out of control.  I have taken some severe hits because of my insistence on staying compliant, but fortunately, I was able to raise enough capital to weather the storm. This past year we were the first company to be licensed in San Francisco, at a time when many other companies were washed out or went back to the black market.

AR: And how is Constance Therapeutics reaching markets outside of California?

CF: One of our foremost challenges was the regulatory bottleneck that prevented us from meeting the tremendous global interest in our THC and CBD products.  I now have a company in Canada, which gives me the ability to legally export my products into the EU and elsewhere. I also worked for years with a team of attorneys to develop legal and commercial frameworks for licensing across jurisdictional lines. This includes a reverse-licensing model, where we provide high quality, evidence-based cannabis R&D, manufacturing and distribution for out-of-state companies that want to reach the California market.  

AR: You’ve said that R&D is what excites you most. Are you finding time for that?

CF: I love developing high quality, evidence-based products from cannabis. Lately I’ve been getting to work with a whole crop of women entrepreneurs who are well capitalized and brilliant, to develop products for the California marketplace.

AR: And to summarize?

CF: I think mine is an inspiring story, in terms of healthcare but also from an entrepreneurial perspective. Ten years ago I was ill and housebound, and this past year I spoke in 10 different countries. If anyone still believes in the demotivation syndrome associated with cannabis, I’m happy to debunk that myth! There is a secret brotherhood and sisterhood of people who are some of the most accomplished and energetic in the world who use a lot of cannabis.

 

Abbie Rosner is a writer specializing in crafting profiles of cannabis industry leaders.  abbieros@gmail.com

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Abbie Rosner

Network Partners

Follow Us on Social Media

LinkedIn

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading